Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption.
Donn J ColbyMichal SarneckiDan H BarouchSomporn TipsukDaniel J StiehEugène KroonAlexandra SchuetzJintana IntasanCarlo SacdalanSuteeraporn PinyakornPornsuk GrandinHongshuo SongSodsai TovanabutraZhanna ShubinDohoon KimDominic Paquin-ProulxMichael A EllerRasmi ThomasMark de SouzaLindsay WieczorekVictoria R PolonisAmélie PagliuzzaNicolas ChomontLauren PeterJoseph P NkololaJohan VingerhoetsCarla TruyersMaria G PauHanneke SchuitemakerNittaya PhanuphakNelson MichaelMerlin L RobbFrank L TomakaJintanat AnanworanichPublished in: Nature medicine (2020)
We administered Ad26, modified vaccinia Ankara vectors containing mosaic HIV-1 antigens or placebo in 26 individuals who initiated antiretroviral therapy during acute human immunodeficiency virus infection as an exploratory study to determine the safety and duration of viremic control after treatment interruption. The vaccine was safe and generated robust immune responses, but delayed time to viral rebound compared to that in placebo recipients by only several days and did not lead to viremic control after treatment interruption (clinical trial NCT02919306).
Keyphrases
- antiretroviral therapy
- hiv infected
- hiv positive
- human immunodeficiency virus
- hiv infected patients
- hiv aids
- clinical trial
- immune response
- double blind
- sars cov
- phase iii
- endothelial cells
- liver failure
- dendritic cells
- open label
- induced pluripotent stem cells
- study protocol
- hiv testing
- hepatitis c virus
- placebo controlled
- intensive care unit
- randomized controlled trial
- pluripotent stem cells
- men who have sex with men
- newly diagnosed
- hepatitis b virus
- gene therapy
- extracorporeal membrane oxygenation